Illumina and Mayo Clinic Form Bioinformatics Relationship to Advance Genetic Disorder Testing
November 10 2016 - 9:00AM
Business Wire
Relationship provides Mayo Clinic early access
to next-generation sequencing technologies; Illumina will obtain
insights for ongoing product development
Illumina, Inc. (NASDAQ: ILMN) today announced it has entered an
agreement with Mayo Clinic to make advancements in next-generation
sequencing technology with the intent to accelerate Mayo’s delivery
of genetic and genomic expertise.
Together, the organizations plan to integrate existing services
and software tools and employ new, innovative solutions to improve
Mayo Clinic’s reporting workflows for researching inherited
disease, enabling Illumina to develop an informatics platform and
knowledge base that can improve and automate genomic
interpretation.
As part of the agreement, Mayo Clinic will implement BaseSpace
Clarity LIMS in specific laboratories to provide testing of the
tool. BaseSpace Clarity LIMS is a system to provide comprehensive
workflow tracking and integration in laboratories. Mayo Clinic will
also deploy and provide feedback on its use of BaseSpace Sequence
Hub, a cloud-based genomics computing environment for data analysis
and management, and BaseSpace Variant Interpreter, a cloud-based
interpretation and reporting platform designed to decrease the time
and effort required to assess biological insight from genomic data.
The software solutions will be piloted by Mayo Clinic to annotate
and interpret genetic variants with regard to their potential role
in the development and progression of diseases.
“Through this relationship, we will be able to generate large
volumes of genomic information, interrogate the data, and then
compare it to what’s known about those variants and those genetic
aberrations in real time, saving our geneticists time,” said
William Morice, II, M.D., Ph.D., chair of Mayo’s Department of
Laboratory Medicine and Pathology and president of Mayo Medical
Laboratories. “We are pleased to work with Illumina and to leverage
each other’s expertise in genetic sequencing and analysis.”
“Mayo Clinic has been at the forefront of advanced medical
research and patient care for a long time,” said Sanjay Chikarmane,
senior vice president and general manager of Illumina Enterprise
Informatics. “BaseSpace Informatics Suite has the ability to
provide a cloud-based software solution that can manage, analyze
and interpret data automatically. We’re pleased that our offering
will help Mayo Clinic make sense of genomic data faster and more
accurately.”
About BaseSpace Informatics Suite
BaseSpace Informatics Suite tools and solutions allow users to
manage and process data in one, secure unified system, from
laboratory information management and data storage, to analysis and
interpretation. This seamless integration between tools and
solutions enables users to save time by automating the process from
the initial sample intake to getting a report about genomic data,
and provides high-quality, accurate information with a fast
turnaround time.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical
practice, education, and research, providing expert, whole-person
care to everyone who needs healing. For more information,
visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.
About Mayo Medical Laboratories/Department of Laboratory
Medicine and Pathology
The Mayo Clinic Department of Laboratory Medicine and Pathology
and its reference laboratory Mayo Medical Laboratories provide
advanced laboratory testing and pathology services to support 5,000
health care organizations around the world. Revenue from this
testing is used to support medical education and research at Mayo
Clinic, a nonprofit worldwide leader in medical care, research, and
education for people from all walks of life. Complemented by
collaborations with diagnostic and biotechnology companies, the
department maintains a robust diagnostic test-development program,
launching more than 150 new tests each year.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161110005123/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243ir@illumina.comorMedia:Mina Nicoletti,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024